PSA level three months after radiation tx may predict outcome

PSA level three months after radiation tx may predict outcome

(HealthDay)—Prostate-specific antigen (PSA) levels three months after radiotherapy (RT) are strong markers of prostate cancer outcomes for patients with intermediate- and high-risk disease, according to a study published online May 4 in Cancer.

Alex K. Bryant, from University of California at San Diego, and colleagues used Veterans Affairs data to identify 5,783 with intermediate-risk or high-risk localized prostate cancer who were diagnosed between 2000 and 2015 and treated with RT and androgen deprivation therapy. Patients were characterized by three-month post-RT PSA values: <0.10 ng/mL, 0.10 to 0.49 ng/mL, and ≥0.50 ng/mL.

The researchers found that a higher three-month PSA level was strongly associated with biochemical progression-free survival (bPFS), prostate -specific survival (PCSS), and overall survival (OS). Greater hazards were noted for patients with a three-month PSA level ≥0.50 ng/mL versus a three-month PSA value <0.10 ng/mL (hazard ratios: bPFS, 5.23; PCSS, 3.97; and OS, 1.50 [P < 0.001 for all]). Greater hazards were also seen for patients with a three-month PSA value of 0.10 to 0.49 ng/mL (hazard ratios: bPFS, 2.41 [P < 0.001]; PCSS, 2.29 [P < 0.001]; and OS, 1.21 [P = 0.003]). When analyzed separately, three-month PSA levels were found to be predictive of OS in the high-risk group (P < 0.001) but not the intermediate-risk group (P = 0.21).

"The three-month PSA measurement may augment clinical decision making and holds promise as a potential surrogate end point in clinical trials," the authors write.

More information: Abstract/Full Text (subscription or payment may be required)

Journal information: Cancer

Copyright © 2018 HealthDay. All rights reserved.

Citation: PSA level three months after radiation tx may predict outcome (2018, May 24) retrieved 25 September 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Dose-escalated radn does not up survival in localized prostate CA


Feedback to editors